Key result
Intravenous immunoglobulin therapy significantly reduced in-hospital mortality (OR 0.44) and improved left ventricular ejection fraction in patients with acute myocarditis.
Why the study?
The efficacy of intravenous immunoglobulin (IVIG) in treating acute myocarditis remains controversial.
Does intravenous immunoglobulin (IVIG) therapy reduce in-hospital mortality and improve left ventricular function in children and adults with acute myocarditis?
Meta-Analysis (n=1,534)
Does intravenous immunoglobulin (IVIG) therapy reduce in-hospital mortality and improve left ventricular function in children and adults with acute myocarditis?
Odds Ratio: 0.44 (95% CI 0.17–0.71)
p-value: p=< 0.001
In a meta-analysis of 1,534 patients, IVIG therapy was associated with significantly lower in-hospital mortality and improved left ventricular ejection fraction in children and adults with acute myocarditis.
No takes yet. Share an insight, caveat, or question.
IVIG may warrant consideration in acute myocarditis; extends prior insufficient evidence in a 1534-patient meta-analysis.
Huang et al. (2019) conducted a meta-analysis in Acute myocarditis and acute fulminant myocarditis (n=1,534). Intravenous Immunoglobulin (IVIG) vs. No IVIG therapy was evaluated on In-hospital mortality (OR 0.44, 95% CI 0.17 to 0.71, p=< 0.001). Intravenous immunoglobulin therapy significantly reduced in-hospital mortality (OR 0.44) and improved left ventricular ejection fraction in patients with acute myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: